- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Study Explores Neoantigen Vaccine With Immune Checkpoint Blockade in Metastatic MSS-CRC
January 17, 2022
The phase 2/3 GRANITE-CRC-1L clinical trial has been initiated.
The Promise of Tislelizumab in Unresectable HCC
January 17, 2022
Ghassan K. Abou-Alfa, MD, discusses the use of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma, as investigated in a phase 2 clinical trial.
Nivo-Ipi Consolidation Fails to Demonstrate Long-Term Survival Advantage Over Placebo in SCLC
January 17, 2022
The immunotherapy combination of nivolumab and ipilimumab did not extend progression-free survival in patients with small cell lung cancer when compared with placebo.
Roundtable Discussion: Pagel Walks Through Treatment Choices in Chronic Lymphocytic Leukemia
January 16, 2022
During a Targeted Oncology live event, John M. Pagel, MD, PhD, and participants discussed their experiences with BTK inhibitors such as acalabrutinib and ibrutinib in terms of efficacy and tolerability as well as other treatment options in patients with chronic lymphocytic leukemia.
Hegde Considers Combination Regimens for NSCLC With PD-L1 Expression 1% or Higher
January 16, 2022
During a Targeted Oncology live event, Aparna Hegde, MD, discussed the results of the KEYNOTE-189 study of pemetrexed and pembrolizumab, the KEYNOTE-042 study of single-agent pembrolizumab, and the CheckMate 227 study of nivolumab and ipilimumab in patients with non–small cell lung cancer.
Nowakowski Considers CD19 Therapy in Transplant-Ineligible DLBCL
January 15, 2022
During a Targeted Oncology live event, Grzegorz S. Nowakowski, MD, discussed the case of a patient treated with tafasitamab plus lenalidomide in the second line for diffuse B-cell lymphoma.
Shammo Debates the Triggers for Treatment of Patients With High-Risk Myelofibrosis
January 14, 2022
During a Targeted Oncology case-based virtual event, Jamile M. Shammo, MD, discussed testing, risk assessment, and therapy for patients with high-risk myelofibrosis.
Part 2: Daratumumab Shows Greater PFS Benefit Early On in Multiple Myeloma
January 14, 2022
During a live virtual event, Saad Zafar Usmani, MD, discussed the findings of the CASSIOPEIA and GRIFFIN studies of daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma.
Exploring Treatment With ViPOR in Mantle Cell Lymphoma
January 14, 2022
National Cancer Institute expert, Christopher J. Melani, MD, discusses the synergy of 5 drugs that make up a targeted therapy regimen for patients with mantle cell lymphoma.
Paclitaxel/Carboplatin Demonstrates Noninferiority to Paclitaxel/Ifosfamide in Uterine Carcinosarcoma
January 14, 2022
Phase 3 study findings show that paclitaxel combined carboplatin stands up to the combination of paclitaxel and ifosfamide for the treatment of patients with uterine carcinosarcoma.
Looking Toward the Future of Endometrial Cancer Management
January 14, 2022
Reflections on the future management of endometrial cancer and practical advice for practicing oncologists.
Novel Strategies Being Investigated in Endometrial Cancer
January 14, 2022
Brian Slomovitz, MD, MS, FACOG, shares excitement for novel and combination therapies being investigated in the endometrial cancer landscape.